Android app on Google Play

Valeant Pharmaceuticals (VRX) Near Deal to Acquire Actavis (ACT) for Over $13B

April 26, 2013 7:28 PM EDT Send to a Friend
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) is near a deal to acquire Actavis (NYSE: ACT) for more than $13 billion, according to late reports from the Wall Street Journal. If consummated it would be one of the largest health-care deals of the year.

The deal is being envisioned as an all-stock transaction but talks are still fragile and could break off, the Journal said.

You May Also Be Interested In

Related Categories

Hot M&A, Mergers and Acquisitions, Rumors, Trader Talk

Add Your Comment